Age-dependency of mycophenolate mofetil dosing in combination with tacrolimus after pediatric renal transplantation

Transplantation Proceedings
G FillerN Lepage

Abstract

Dosing of mycophenolate mofetil (MMF) must be lower in combination therapy with Tacrolimus (Tac) than with Cyclosporine. One study with mostly adolescent recipients recommended an MMF dose of 250 mg/m2 BID. Because this dose resulted in low area-under-the-curve (AUC) in our infant population, we retrospectively analyzed all available pharmacokinetic (PK) profiles in pediatric renal transplant patients on MMF plus Tac therapy to propose appropriate MMF dosing in pediatric patients of all ages. Forty-four PK profiles were performed in 27 patients (median age, 11.6 years; range, 1.8-20.7 years). The investigations were performed at a median of 299 days (range, 24-3424) after transplantation. Ten patients were converted to Tac plus MMF, all others received this as primary therapy. For patients with repeated measurements, we calculated the average AUC and doses. We used first-order PK modeling to calculate the doses for a mycophenolic acid (MPA) AUC of 60 ug*h/mL and a Tac AUC of 150 ng*h/mL. The mean Tac dose was 2.6 +/- 1.2 mg/m2/d or 0.086 +/- 0.038 mg/kg/d, resulting in an average AUC of 120.6 +/- 30.4 ng*h/mL. The MMF dose was not normally distributed; the median dose was 549 mg/m2/d (range, 146-1413) and the median MPA AUC was...Continue Reading

References

Jul 17, 1998·Transplant International : Official Journal of the European Society for Organ Transplantation·G FillerJ H Ehrich
Feb 23, 2000·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·E Jacqz-AigrainC Loirat
Feb 23, 2000·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·G FillerI Mai
Aug 8, 2002·Kidney International·Dario CattaneoGiuseppe Remuzzi
Aug 15, 2002·Transplantation Proceedings·N J A WebbN A Undre
Aug 2, 2003·Pediatric Transplantation·L PapeG Offner
Jan 6, 2004·International Journal of Clinical Pharmacology and Therapeutics·P GlanderK Budde

❮ Previous
Next ❯

Citations

Mar 12, 2013·Clinical Pharmacokinetics·Azrin N Abd RahmanChristine E Staatz
Jul 11, 2006·The British Journal of Ophthalmology·D DoychevaM Zierhut
Jul 3, 2008·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·Sabine IrtanEvelyne Jacqz-Aigrain
Mar 25, 2014·Expert Opinion on Drug Safety·Alessandro CeschiAnne B Taegtmeyer
Apr 2, 2014·Expert Opinion on Drug Safety·Guido Filler, Amaryllis Ferrand
Jul 26, 2006·Expert Opinion on Drug Metabolism & Toxicology·Jill S Warrington, Leslie M Shaw
Jul 26, 2006·Expert Opinion on Drug Metabolism & Toxicology·Maria ShipkovaEberhard Wieland
Jan 9, 2016·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·Elisa C YooGuido Filler
Mar 1, 2016·Pediatric Transplantation·Lisa C MartialRoger J M Brüggemann
Dec 30, 2015·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·Guido Filler, Lisa A Robinson
May 26, 2007·Transplantation Proceedings·G Filler
May 11, 2007·The British Journal of Dermatology·M HellerJ V Schaffer
Apr 24, 2012·British Journal of Clinical Pharmacology·Heather J DowningRosalind L Smyth
Apr 22, 2010·British Journal of Clinical Pharmacology·Wei ZhaoEvelyne Jacqz-Aigrain
Jul 1, 2014·Pediatric Transplantation·Rodrigo González-RamírezMara Medeiros
Aug 16, 2014·Pediatric Transplantation·Guido Filler, Marta Kobrzyński
Dec 14, 2011·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Brett GlotzbeckerRobert Soiffer
Feb 28, 2016·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·Guido FillerMara Medeiros
Oct 6, 2018·Modern Rheumatology·Haruna NakasekoMasaaki Mori
Apr 22, 2006·Therapeutic Drug Monitoring·Teun van GelderRichard D Mamelok
Nov 14, 2006·Pediatric Transplantation·Raman Venkataramanan, Rakesh Sindhi
Nov 12, 2010·Therapeutic Drug Monitoring·Wei ZhaoEvelyne Jacqz-Aigrain
Oct 28, 2005·Transplantation·Robert Ettenger, Minnie M Sarwal
Mar 28, 2008·Therapeutic Drug Monitoring·Guido FillerUwe Christians
Mar 9, 2012·Clinical Pharmacology and Therapeutics·M L Becker
Dec 25, 2013·Therapeutic Drug Monitoring·Guido FillerNorman Muirhead
Jun 3, 2020·Clinical Transplantation·Pâmela C Lukasewicz FerreiraPedro Eduardo Fröehlich
Jan 6, 2019·European Journal of Clinical Pharmacology·Pâmela C Lukasewicz FerreiraPedro Eduardo Fröehlich
Oct 30, 2020·British Journal of Clinical Pharmacology·Yan RongTony K L Kiang
Jun 15, 2021·Expert Opinion on Drug Metabolism & Toxicology·Kathleen M JobCatherine M Sherwin

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons
G FillerUwe Christians
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons
Marika SchubertRakesh Sindhi
© 2022 Meta ULC. All rights reserved